![](https://www.ontario.ca/misc/message-24-info.png)
Important: This version of the e-Laws website will be upgraded to a new version in the coming weeks.
You can try the beta version of the new e-Laws at ontario.ca/laws-beta.
![](/sites/all/themes/ontario/images/ontario-black@2x.png)
O. Reg. 54/06: GENERAL
filed March 3, 2006 under Drug Interchangeability and Dispensing Fee Act, R.S.O. 1990, c. P.23
Skip to contentontario regulation 54/06
made under the
drug interchangeability and dispensing fee act
Made: March 1, 2006
Filed: March 3, 2006
Published on e-Laws: March 6, 2006
Printed in The Ontario Gazette: March 18, 2006
Amending Reg. 935 of R.R.O. 1990
(General)
1. (1) The definition of “Formulary” in subsection 1 (1) of Regulation 935 of the Revised Regulations of Ontario, 1990 is revoked and the following substituted:
“Formulary” means the Ministry of Health and Long-Term Care publication titled “Drug Benefit Formulary/Comparative Drug Index” (No. 39) dated September 27, 2005, and includes the following amendments to the publication:
1. Amendments dated January 12, 2006.
2. Amendments dated April 19, 2006;
(2) Subsection 1 (1.1) of the Regulation is revoked.
(3) Section 1 of the Regulation is amended by adding the following subsection:
(1.3) For the purposes of this Regulation, item 231 of Part III of the Formulary shall be read as follows:
231 |
2.5 mg Tab |
|
|
4.9500 |
|
02231384 |
Femara (Letrozole) |
NOV |
4.9500 |
|
Reason for Use Code |
Clinical Criteria |
||
|
365 |
For the treatment of metastatic breast cancer in hormone receptor positive postmenopausal women. LU Authorization Period: Indefinite. |
||
|
403 |
For the treatment of hormone receptor positive early breast cancer in postmenopausal women who have received 5 years of adjuvant tamoxifen therapy. LU Authorization Period: 5 Years. |
2. This Regulation comes into force on April 19, 2006.